ArticleDiscover oncology2026
Computational identification of diagnostic biomarkers linking Dibutyl phthalate exposure to ovarian cancer through network toxicology and machine learning.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDibutyl phthalate (DBP), a widely used plasticizer, has been implicated in various health concerns, including potential carcinogenic effects. However, the molecular mechanisms underlying DBP’s toxicological effects on ovarian cancer remain poorly understood. This study aimed to computationally investigate the potential association between DBP and ovarian cancer through network toxicology and bioinformatics approaches.
methodsTranscriptomic data from GSE26712 identified ovarian cancer-related differentially expressed genes (DEGs). DBP targets were curated from SEA, SwissTargetPrediction, CTD, and TargetNet. Intersecting genes were analyzed via protein-protein interaction (PPI) networks, functional enrichment, and gene set variation analysis (GSVA). Machine learning (SVM, LASSO, RF) pinpointed key targets, validated through ROC analysis, molecular docking, tumor immune infiltration assessment, and immunofluorescence staining of clinical samples.
resultsWe identified 27 shared targets linking DBP to ovarian cancer, with CTNNB1, SOD2, and KDR as central PPI nodes. Enriched pathways included Wnt signaling, apoptosis, immune responses, and fatty acid biosynthesis. GSVA highlighted dysregulation in T-cell proliferation, cytokine activity, and hypoxia response. Machine learning converged on three key genes: KDR, ANXA3, and FOLR1. ROC analysis confirmed exceptional diagnostic accuracy. These genes correlated significantly with immune infiltration. Molecular docking revealed strong DBP binding to targets. Immunofluorescence validated differential protein expression: KDR, and ANXA3 were downregulated, while FOLR1 was upregulated in cancer tissues.
conclusionThis integrative computational study reveals a potential molecular link between DBP and ovarian cancer, proposing that DBP may influence ovarian cancer-associated pathways. The identified hub genes KDR, ANXA3, and FOLR1 represent promising diagnostic biomarkers. Our findings provide a hypothesis-generating framework suggesting that DBP exposure could contribute to ovarian carcinogenesis by disrupting key biological pathways and modulating the tumor immune microenvironment, warranting further experimental investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.